Raynovent focuses on the innovative drugs development for the treatment of influenza, Non-Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF), etc., on the strength of our comprehension and insights of respiratory and liver diseases.
For ZSP1273, the influenza drug candidate which are of highly commercial value and public health emergency, we are going to simultaneously develop oral solid dosage form, granule formulation, inhalation formulation, etc. for different people, including adults, children, and critically ill patients.
To address the urgent unmet need of the global epidemic, NASH, our pipeline has covered diverse targets in the liver disease progression and of good potential for combination therapy, such as steatosis, inflammation, fibrosis, etc.